MBX Biosciences (NASDAQ:MBX) Shares Gap Down - Should You Sell?

Key Points

• MBX Biosciences gapped down at the open, falling from a prior close of $60.04 to an opening price of $52.82 before trading around $55.83.
• Analyst sentiment remains mixed but constructive overall: the stock has a Moderate Buy consensus rating with an average price target of $60.22, though one analyst still rates it a sell.
• The company is a clinical-stage biopharmaceutical firm focused on precision peptide therapies for endocrine and metabolic disorders, and its shares have drawn notable institutional buying in recent quarters.

MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $60.04, but opened at $52.82. MBX Biosciences shares last traded at $55.83, with a volume of 305,802 shares changing hands.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Citigroup reiterated an "outperform" rating on shares of MBX Biosciences in a report on Tuesday, May 12th. Lifesci Capital raised shares of MBX Biosciences to a "strong-buy" rating in a research report on Tuesday, March 31st. Weiss Ratings restated a "sell (d-)" rating on shares of MBX Biosciences in a report on Tuesday, April 21st. Citizens Jmp lifted their price objective on shares of MBX Biosciences from $76.00 to $86.00 and gave the company a "market outperform" rating in a report on Tuesday, May 12th. Finally, Wall Street Zen upgraded MBX Biosciences from a "sell" rating to a "hold" rating in a report on Sunday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, MBX Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $60.22.

MBX Biosciences Stock Performance

The firm has a market capitalization of $2.65 billion, a PE ratio of -25.08 and a beta of 0.16. The company's 50 day simple moving average is $40.94 and its 200-day simple moving average is $36.11.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MBX. Russell Investments Group Ltd. raised its holdings in MBX Biosciences by 4,131.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company's stock valued at $26,000 after buying an additional 1,446 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of MBX Biosciences in the third quarter worth about $27,000. GF Fund Management CO. LTD. purchased a new position in MBX Biosciences during the 4th quarter valued at about $28,000. Strs Ohio raised its position in MBX Biosciences by 128.6% during the 1st quarter. Strs Ohio now owns 1,600 shares of the company's stock valued at $48,000 after purchasing an additional 900 shares during the last quarter. Finally, Royal Bank of Canada raised its position in MBX Biosciences by 59.6% during the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company's stock valued at $49,000 after purchasing an additional 572 shares during the last quarter.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.